Last Transcript: Pila Pharma AB

Pila Pharma AB, H2 2025 Earnings Call, Feb 10, 2026

02-10

More transcripts

Analysts' recommendations: Pila Pharma AB

09-01

Pila Pharma moves to higher doses - Biostock

More recommendations

Press Releases: Pila Pharma AB

10-02	PILA PHARMA launches new obesity study	AQ
10-01	Obesity trial gets underway for Pila Pharma	AQ
09-30	PILA PHARMA: FIRST SUBJECT FIRST VISIT COMPLETED FOR SAFETY PART 1 OF PP-CT04, A CLINICAL TRIAL IN PEOPLE LIVING WITH OBESITY	AQ
09-29	PILA PHARMA: FIRST CLINICAL SITE INITIATED AND ACTIVATED, ENROLLMENT COMMENCES FOR SAFETY PART 1 OF PP-CT04, A 12-WEEK CLINICAL TRIAL IN PEOPLE LIVING WITH OBESITY	AQ
09-08	PILA PHARMA: ALL RECENT H1 REPORT AND MANAGEMENT INTERVIEWS NOW ONLINE	AQ

More press releases

Managers and Directors: Pila Pharma AB

Manager	Title	Age	Since
Gustav Hanghøj Gram CEO	Chief Executive Officer	33	2024-03-31
Dorte Xenia Gram CEO	Chief Executive Officer	57	2013-12-31
Hampus Darrell DFI	Director of Finance/CFO	-	2024-12-16

Director	Title	Age	Since
Dorte Xenia Gram CHM	Chairman	57	2024-03-31
Richard Busellato BRD	Director/Board Member	59	2023-05-29
Julie Waras Brogren BRD	Director/Board Member	54	2024-03-31

More insiders

Pila Pharma AB is a Sweden-based clinical stage pharmaceutical company, active in the biotechnology sector. The Company conducts clinical tests in phase 2 with drugs against type 2 diabetes. The target product is a tablet that is taken orally in an early stage of diabetes to restore the body's insulin production and thereby reduce the patient's blood sugar level. PILA PHARMA's patent-protected product candidate is called XEN-D0501 and is a TRPV1 antagonist, a novel type of oral anti-diabetic agent for treatment of type 2 diabetes. Pila Pharma AB has completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes. In addition, the product is expected to have fewer unwanted side effects than alternative forms of treatment.

Employees

Sector

Pharmaceuticals

Calendar

02-25 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-10-05	SEK 1.675	-3.74%	12,150
26-10-02	SEK 1.740	-7.20%	71,483
26-10-01	SEK 1.875	-0.79%	95,907
26-09-30	SEK 1.890	+2.16%	85,426
26-09-29	SEK 1.850	+8.19%	78,294

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Delayed Nasdaq Stockholm 03:04:58 2026-10-05 EDT			5-day change	1st Jan Change
1.675 ^SEK	-3.74%		-2.05%	-18.69%

09-30	Pila Pharma launches safety portion of obesity study	FW
09-29	Pila Pharma begins recruitment for obesity study	FW

Market Cap	79.49M 7.92M 7.04M 6.57M 5.99M 11.29M 761M 11.4M 30.8M 389M 29.74M 29.09M 1.25B	P/E 2026 *	-13.4x	P/E 2027 *	-7.57x
Enterprise Value	47.49M 4.73M 4.2M 3.92M 3.58M 6.75M 455M 6.81M 18.4M 233M 17.77M 17.38M 746M	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	65.44%	Yield 2026 *	-	Yield 2027 *	-

09-30	Pila Pharma launches safety portion of obesity study	FW
09-29	Pila Pharma begins recruitment for obesity study	FW
09-01	Pila Pharma moves to higher doses - Biostock	FW
08-28	PILA PHARMA: New obesity study approved, CEO on the first half and the next big step	FW
08-27	Pila Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-27	Pila Pharma Publishes Interim Report and Provides Update on Clinical Trial of Oral Trpv1 Antagonist for Obesity and Diabetes	CI
08-27	Pila Pharma posts small earnings changes, CEO: taken a major step forward	FW
08-18	Pila Pharma Wins EU Nod for Trial Testing Erythromelalgia Drug in Obese Participants	MT
08-18	Pila Pharma gets green light for obesity study	FW
08-18	Pila Pharma AB Receives Regulatory Approval to Conduct PP-CT04, a 12-Week Trial Exploring the Safety and Efficacy of XEN-D0501 in People Living with Obesity	CI
07-31	Pila Pharma chairman shifts shares, holding unchanged (update)	FW
07-31	Pila Pharma chair buys shares for nearly $0.6m	FW
04-16	Pila Pharma: Low exposure behind lack of weight effect in rat study	FW

1 day	-3.74%
1 week	-2.05%
Current month	-11.38%
1 month	-10.43%
3 months	+37.86%
6 months	-6.94%
Current year	-18.69%

Pila Pharma AB Stock

Stocks

PILA

SE0015988274

Pharmaceuticals

Valuation: Pila Pharma AB

Chart: Pila Pharma AB

Latest news: Pila Pharma AB

Last Transcript: Pila Pharma AB

Analysts' recommendations: Pila Pharma AB

Press Releases: Pila Pharma AB

Quotes and Performance

Price Extremes

Managers and Directors: Pila Pharma AB

Other Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

1 week	1.61	1.94
1 month	1.4	2.39
Current year	1.02	2.5
1 year	1.02	2.5
3 years	0.99	9.2
5 years	0.99	9.2
10 years	0.99	12.9

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PILA PHARMA AB	-3.74%	-2.05%	-28.42%	-12.53%	7.92M
ELI LILLY AND COMPANY	-0.61%	-3.43%	+36.07%	+115.04%	1,019B
JOHNSON & JOHNSON	-1.02%	-5.60%	+35.72%	+64.63%	617B
ABBVIE INC.	+1.11%	-0.58%	+12.36%	+77.95%	464B
MERCK & CO., INC.	+0.34%	-3.01%	+61.79%	+41.24%	356B
ROCHE HOLDING AG	+0.04%	-2.73%	+19.87%	+40.13%	333B
NOVARTIS AG	+0.80%	-3.33%	+10.93%	+34.54%	267B
ASTRAZENECA PLC	+0.13%	-4.90%	-6.65%	+8.97%	244B
AMGEN INC.	-1.04%	-2.79%	+35.30%	+51.84%	218B
GILEAD SCIENCES, INC.	-1.87%	-4.10%	+28.44%	+93.66%	179B
Average	-0.58%	-3.07%	+20.54%	+51.55%	369.72B
Weighted average by Cap.	-0.24%	-3.54%	+29.01%	+70.55%

	2026 *	2027 *
Net sales	-	-
Net income	-7M -698K -620K -578K -527K -994K -67.05M -1M -2.71M -34.28M -2.62M -2.56M -110M	-19M -1.89M -1.68M -1.57M -1.43M -2.7M -182M -2.72M -7.36M -93.04M -7.11M -6.95M -299M
Net Debt	-32M -3.19M -2.83M -2.64M -2.41M -4.55M -307M -4.59M -12.4M -157M -11.97M -11.71M -503M	-13M -1.3M -1.15M -1.07M -979K -1.85M -125M -1.86M -5.04M -63.66M -4.86M -4.76M -204M

Markets		Quality
Nasdaq Stockholm	PILA	Delayed
Deutsche Boerse AG	5KC	Delayed